ABSTRACT
OBJECTIVE: To improve the short-term postoperative outcomes in patients with thymoma stage I-II by using of thoracoscopic thymectomy (VATS TE) and to compare this technique with open (OTE) thymectomy. MATERIAL AND METHODS: A retrospective analysis included 98 patients who had undergone surgery for thymoma stage I and II for the period from January 2001 to December 2019. VATS TE (main group) was performed in 53 (54.1%) cases, OTE (control group) - in 45 (45.9%) patients. RESULTS: Duration of VATS TE and OTE was similar. VATS procedure was characterized by less intraoperative blood loss (50 vs 225 ml, p=0.000), lower pain scores and morphine consumption (p=0.000), shorter postoperative pleural drainage (1.5 vs 3.8 days, p=0.000), and postoperative hospital-stay (7.6 vs 12.7 days, p=0.000). Incidence of major complications was significantly less in the main group (9.4% vs. 1.9%, p=0.001). CONCLUSION: VATS TE is effective and safe procedure for thymoma stage I-II. Postoperative period after VATS TE is characterized by less intraoperative blood loss, incidence of complications, duration of pleural drainage and hospital-stay.
Subject(s)
Thymoma , Thymus Neoplasms , Humans , Neoplasm Staging , Retrospective Studies , Thoracic Surgery, Video-Assisted , Thymectomy/adverse effects , Thymoma/diagnosis , Thymoma/surgery , Thymus Neoplasms/diagnosis , Thymus Neoplasms/surgery , Treatment OutcomeABSTRACT
The paper is devoted to assessment of isometronidazole tolerance, used as a radiosensitizer for preoperative irradiation of lung cancer patients, and to characterization of morphological postradiation changes in tissues of carcinomas removed at operation. Isometronidazole was shown to cause no severe side-effects in patients, improving considerably radiation injury of the tumor parenchyma.
Subject(s)
Lung Neoplasms/radiotherapy , Metronidazole/analogs & derivatives , Radiation-Sensitizing Agents/therapeutic use , Adult , Combined Modality Therapy , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/surgery , Male , Metronidazole/therapeutic use , Middle AgedABSTRACT
The authors studied the effect of extrapulmonary spread of the primary tumor on the prognosis of epidermoid carcinoma of the lung. The outcome of the disease in such spread of carcinoma is also determined by the condition of the regional lymph nodes and the localization, area, and depth of the invasion. Different variants of adjuvant radiotherapy improve on the whole the late-term results of combined operations.
Subject(s)
Carcinoma, Squamous Cell/surgery , Lung Neoplasms/surgery , Adult , Aged , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Humans , Lung Neoplasms/pathology , Lymphatic Metastasis , Mediastinal Neoplasms/etiology , Mediastinal Neoplasms/secondary , Middle Aged , Neoplasm Invasiveness , Preoperative Care , Prognosis , Radiation DosageSubject(s)
Adenocarcinoma/therapy , Bronchi/surgery , Carcinoma, Squamous Cell/therapy , Lung Neoplasms/therapy , Preoperative Care , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Pneumonectomy , Postoperative Complications/epidemiology , Radiotherapy DosageABSTRACT
An anatomo-topographic and operative study aimed at the elaboration of approaches and methods of the catheterization of the thoracic lympheduct and of the selective catheterization of the internal thoracic, external thoracic and acromiothoracic arteries for the regional infusion of activated proper lymphocytes and chemopreparations in breast cancer was carried out on 25 cadavers. An experimental injection of stained solutions proved that the selective catheterization of the thoracic arteries allows to create a significant concentration of injected drugs in the breast and regional lymphatic nodes without their propagation into adjacent regions, which is different from other methods of the regional chemotherapy in breast cancer.